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Abstract
Innate immunity involving antimicrobial peptides represents an integrated and highly effective system of molecular and
cellular mechanisms that protects host against infections. One of the most frequent hospital-acquired pathogens,
Staphylococcus aureus, capable of producing proteolytic enzymes, which can degrade the host defence agents and tissue
components. Numerous antimicrobial peptides derived from chromogranins, are secreted by nervous, endocrine and
immune cells during stress conditions. These kill microorganisms by their lytic effect at micromolar range, using a pore-
forming mechanism against Gram-positive bacteria, filamentous fungi and yeasts. In this study, we tested antimicrobial
activity of chromogranin A-derived peptides (catestatin and cateslytin) against S. aureus and analysed S. aureus-mediated
proteolysis of these peptides using HPLC, sequencing and MALDI-TOF mass spectrometry. Interestingly, this study is the first
to demonstrate that cateslytin, the active domain of catestatin, is active against S. aureus and is interestingly resistant to
degradation by S. aureus proteases.
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Introduction
Chromogranins (Cgs) constitute the predominant family of
proteins enclosed in secretory vesicles of chromaffin cells. [1] They
are naturally processed to produce numerous peptides with various
biological activities. [2–4] During the past decade, our group
characterized several new antimicrobial peptides (AMPs) derived
from chromogranin A (CgA) [5–8] and chromogranin B (CgB).
[3,9] These peptides are released by stimulated chromaffin cells of
adrenal medulla and also by activated polymorphonuclear
neutrophils (PMNs). [5,7] Sequences of these peptides are highly
conserved during evolution, suggesting that they are well-
integrated in innate immune system. [10] Among these AMPs:
chromofungin (CHR, CgA47–66) and catestatin (CAT, CgA344–
364), derived from bovine CgA, activate PMNs and induce a
calcium influx into immune cells. [11].
Staphylococcus aureus is the most frequently isolated pathogen in
Gram-positive sepsis, often involved in blood clotting disorders
and destruction of endocardial tissue. [12] S. aureus has developed
several mechanisms to avoid immune response including resis-
tance to AMPs, [13] impairment of phagocyte recruitment, [14]
escape from neutrophil extracellular traps, [15] interference with
complement, [16] neutrophil lysis, resistance to oxidative burst
[17] and non-specific binding and degradation of immunoglobu-
lins. [18] The AMPs evasion mechanisms deployed by S. aureus
include proteolytic degradation by extracellular proteases of three
major catalytic classes, namely metallo-, serine- and papain-like
cysteine proteases. [19] The expression of proteolytic enzymes is
controlled directly by global regulators of virulence factors such as
agr, sar [20,21] and indirectly by RsbU that controls Sigma(B)
activity.[22] Moreover, SarA is also a regulator of methicillin
resistance factor (fmtA).[23] It has been previously reported that S.
aureus metallo-protease aureolysin can cleave and inactivate
human cathelicidin LL-37, thereby contributing to bacterial
escape from the innate immune system. [13].
As staphylococci easily colonize skin and epithelia, regardless of
the expression of antimicrobial Cgs-derived peptides, [24] we
aimed to investigate the antimicrobial effects of CAT and its
shorter fragment cateslytin (CTL, CgA344–358) against S. aureus.
Taking into account the difference in the activity of these peptides,
using HPLC and proteomic analysis (sequencing and MALDI-
TOF mass spectrometry), we examined the degradation of these
CgA-derived peptides by staphylococcal proteases released into
bacterial supernatants. Here, we report the relationship between
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peptide sequences and their sensitivity to bacterial proteases, as
well as the possibility to use them as new antimicrobial agents in
combination with antibiotics.
Materials and Methods
Preparation and analysis of synthetic antimicrobial
peptides
Synthetic peptides were prepared on an Applied Biosystems
433A peptide synthesizer (Foster City, USA), using the stepwise
solid-phase approach with 9-fluorenylmethoxycarbonyl (Fmoc)
chemistry. Sequences of the synthetic peptides are as follows:
bCAT (bCgA344–364: RSMRLSFRARGYGFRGPGLQL), hCAT
(hCgA352–372: SSMKLSFRARGYGFRGPGPQL), bCTL
(bCgA344–358: RSMRLSFRARGYGFR) and LL-37 (hCAP134–
170 LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES).
Then, the synthetic peptides were purified by a Dionex HPLC
system (Ultimate 3000; Sunnyvale, CA USA) on a Macherey
Nagel Nucleosil RP 300–5C18 column (106250 mm; particle size
5 mm and pore size 100 nm). Synthetic peptides were analysed by
an automated Edman sequencing on an Applied Sequencing
System Procise (Applied Biosystems, Foster City, USA). [9]
Finally, MALDI-TOF mass measurements were carried out on
an UltraflexTM TOF/TOF (BrukerDaltonics, USA), as previously
described. [25].
Isolation and characterization of Staphylococcus aureus
strains
Different S. aureus strains were used to demonstrate the peptide
antimicrobial activity and subsequently, the peptide degradation:
strains ATCC 25923, ATCC49775, S1 and S2, were provided by
the Institute of Bacteriology, Strasbourg, France. S1 was isolated
from the blood of an 83 y. o. patient and S2 was isolated from the
sputum of a 12 days old neonate. After isolation and identification,
S. aureus strains were assessed for their susceptibility to various
antibiotics, using the agar disc diffusion method. [26] S1 was
found Methicillin resistant (MRSA) and is also resistant to
Amoxicillin, Oxacillin, Amikacin, Tobramycin, Fluoroquinolones,
Erythromycin and Clindamycin. However, it was susceptible to
Gentamicin, Synercid, Co-trimoxazole, Rifampicin, Fusidic acid,
Vancomycin, Teicoplanin and Linezolid. In contrast, S2 was
found to be Methicillin susceptible (MSSA) and is sensitive to all
the antibiotics tested.
Antibacterial activity against S. aureus
Different S. aureus strains described above were first pre-cultured
aerobically at 37uC for 20 h in a Mueller-Hinton-Broth (MHB)
medium, pH 7.3 (Difco Laboratories, Detroit, MI). Bacteria were
suspended at absorbance of 0.001 at 620 nm in the MHB
medium. Antibacterial activity was tested for 24 h incubation at
37uC with shaking by measuring the inhibition of bacterial growth.
Ten ml final volumes (10–200 mg/mL) of synthetic peptides (LL-
Figure 1. The bacterial killing kinetics of the bCTL against the S. aureus ATCC 25923. Different concentrations (MIC 40 mg/mL and 26MIC
80 mg/mL) of bCTL were used. C+, represents antibiotic control (Cefotaxime 0.1 mg/mL + Tetracycline 10 mg/mL) and C-, represents phosphate buffer
saline control. (A): S. aureus killing kinetics at time zero to 60 min. (B): S. aureus killing kinetics over 24 h time period.
doi:10.1371/journal.pone.0068993.g001
Table 1. Antibacterial assays of catestatin (bovine, bCAT and human, hCAT) and cateslytin (bovine, bCTL) against different S.
aureus strains, compared to the cathelicidin antimicrobial peptide-18 (LL-37).
Antimicrobial peptides MIC (mg/mL)
S. aureus ATCC49775 S. aureus ATCC25923 S. aureus S1 (MRSA) S. aureus S2 (MSSA)
bCAT 100 aA 100 aA 100 aA 115 bA
hCAT 125 aB 135 aB 130 aB 150 bB
bCTL 37 aC 40 aC 37 aC 45 bC
LL-37 30 aD 30 aD 30 aC 35 bC
Results are presented as MIC (mg/mL) of each peptide against four S. aureus strains. Values represent the means of the triplicate (n = 3) wells. Means with same letters are
not significantly different (p,0.05). Small letters (a, b, c) represents significance between different S. aureus strains, while capital letters (A, B, C) represent significantly
difference between peptides.
doi:10.1371/journal.pone.0068993.t001
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37, bCAT, hCAT and bCTL) were incubated in microtitration
plates with 90 ml of a mid-logarithmic phase culture of bacteria,
with a starting absorbance of 0.001 at 620 nm. In the initial
inoculi, bacteria were quantified by the agar plate spreading
method which was 56105 colony forming units (CFU)/mL. [27]
Tetracycline (10 mg/L) and Cefotaxime (0.1 mg/L) were used as
positive controls. Microbial growth was assessed by the increase of
absorbance after 24 h incubation at 37uC. [28,29] The A620 nm
value of control cultures growing in the absence of peptide and
antibiotics was defined as 100% growth. A620 nm zero with the
antibiotics (Tetracycline and Cefotaxime) was taken as 100%
inhibition. Absence of bacterial growth was verified by agar plate
spreading. Each assay was performed in triplicates.
Killing kinetics
Bacterial strains were first grown in MHB medium as described
above. Bacteria killing kinetic activity was measured according to
the previously described method, after making few modifications.
[30] Initial inoculum was prepared at a concentration of
56105 CFU/mL with absorbance of 0.001 at 620 nm, which
was calculated by agar plate spreading method. [27] Bacteria were
incubated with different concentrations of peptides (MIC and 26
MIC), determined by MIC assay via microdilution method. [27]
Viable bacterial count was then assessed at different time intervals
up to 24 h. Briefly, aliquots were taken at different time intervals
and were diluted in phosphate buffer saline (pH 7.4). After
appropriate shaking 100 mL of the dilutions were plated on MH
agar plates. Plates were incubated at 37uC and colony count was
performed to determine CFU/mL after 24 h.
Preparation of S. aureus supernatants
S. aureus strains were precultured and plated on the agar plates and
cultivated for 24 h at 37uC. After incubation, one colony per isolate
was transferred to 10 mL of the MHB medium and incubated at
37uC for about 30 h to late stationary growth phase. After
incubation, cultures were centrifuged at 10,0006g for 15 min and
supernatants were filtered using a 0.22 mM MillexH-GV (Millipore,
Carrigtwohill, Ireland) to eliminate bacteria. The supernatants were
stored at220uC until further use. In order to check sterility, 1 mL of
each supernatant was incubated at 37uC for 48 h. Absence of a
colony was interpreted as lack of viable bacteria.
Degradation analysis of the synthetic antimicrobial
peptides by S. aureus supernatants
Synthetic peptides catestatin (bovine and human) and cateslytin
(bovine) were incubated at 37uC for 24 h, with the different strain
supernatants, at a concentration corresponding to the MIC values.
Triplicate wells were treated for each concentration of peptide. In
parallel, several controls were performed: with and without
peptides in MHB medium.
In order to prevent degradation, the above experiment was
repeated. For which, protease inhibitor cocktail (complete protease
inhibitors except metalloproteases) (Roche Diagnostic GmbH,
Mannheim, Germany) supplemented with 100 mM of 1–10
phenanthroline (metalloprotease inhibitor) (Sigma Aldrich GmbH,
Steinheim, Germany) was added to bacterial supernatants before
the addition of synthetic peptides. The whole suspension was
incubated at 37uC for 24 h prior to being analyzed by RP-HPLC.
RP-HPLC purification of CgA-derived peptides after
incubation with S. aureus supernatants
The synthetic peptides treated with bacterial supernatants and
different controls including culture medium, bacterial superna-
tants, and synthetic peptides were separated using a Dionex HPLC
system (Ultimate 3000; Sunnyvale, CA USA) on a Nucleosil
reverse-phase 300–5C18-column (46250 mm; particle size, 5 mm;
porosity, 300 A˚) (Macherey Nagel Hoerdt, France). Absorbance
was monitored at 214 nm, and the solvent system consisted of
0.1% (v/v) TFA in water (solvent A) and 0.09% (v/v) TFA in 70%
(v/v) acetonitrile-water (solvent B). Elution was performed at a
flow rate of 700 mL/min, with the gradient as indicated on
chromatograms. Fractions were collected with one min time
interval. They were subsequently concentrated by evaporation by
using a speed-vac, however not allowing them to dry completely.
Automatic Edman sequencing of CgA-derived peptides
The N-terminal sequence of purified peptides was determined
by automatic Edman degradation analysis on a Procise micro-
sequencer (Applied Biosystems, Courtaboeuf, France). Samples
purified by HPLC were loaded on polybrene-treated glass-fiber
filters. Phenylthiohydantoin-amino acids (Pth-Xaa) were identified
by chromatography on a C18 column (PTH C-18,
2.1 mm6200 mm). [2].
Proteomic analysis
Mass determination was carried out on a Brucker BIFLEXTM
Matrix-Assisted Laser Desorption Ionization – Time-Of-Flight
mass spectrometer (MALDI-TOF) (equipped with the high
resolution optics (SCOUTTM) with X–Y multi-sample probe, a
gridless reflector and with the HIMASTM linear detector). With a
maximum accelerating potential of 30 kV, the system can be
operated either in linear or the reflective mode. Ionization was
carried out with a 337-nm beam from a nitrogen laser with a
repetition rate of 3 Hz. The output signal from the detector was
digitized at a sampling rate of 250 MHz in linear mode and
500 MHz in reflector mode using a 1 GHz digital oscilloscope
(Lecroy model). Brucker supplied software hosted in Sun
sparcworkstation was used for data processing and the instrumen-
tal control. [31] These studies were realized using the matrix a-
cyano-4-hydroxycinnamic acid, obtained from Sigma, and
prepared as a saturated solution in acetone. A total of 1–2 ml of
the sample matrix aliquot solution was deposited on the probe and
dried by ambient air. A thin layer matrix crystal was obtained after
rapid spreading and evaporation. [32] A micromolar analyte
solution was applied to the matrix and allowed to dry under
moderate vacuum. The whole preparation was washed by 1 ml of
trifluoroacetic acid (0.5%) aqueous solution. This cleaning
procedure helps remove remaining alkaline cations and often
leads to an increase in sensitivity.
Statistical analysis
The MIC values (mg/mL) are reported as means of three
independent experiments. To determine significance, between
different peptides (rows) and bacterial strains (columns), one way
ANOVA was used. Overall significance and correlation was
evaluated by 464 factorial ANOVA for independent samples.
Significance was accepted at p#0.05.
Results
Antibacterial activity of CgA-derived peptides against S.
aureus
The aim of present study was to examine antibacterial activity
of bovine and human CAT (bCgA344–364 and hCgA352–372) and
bovine CTL (bCgA344–358), against S. aureus. In comparison with
the other peptides tested, CTL was found to be most active against
all S. aureus strains tested (ATCC49775, ATCC25923, S1, and S2).
Cateslytin and S. aureus
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Activity of these CgA derived peptides was compared to the well-
known C-terminal peptide (LL-37) of hCAP-18 (Table 1). Activity
of bCTL was comparable to that of LL-37 (p.0.05) against S1 and
S2, but significantly different (p,0.05) for ATCC49775 and
ATCC25923. However, MIC (presenting 100% growth inhibition)
values for bCAT and hCAT were highly significantly different
(p,0.01) that were about 2–4 fold higher than short fragment
CTL (Table 1). MIC value for CTL varies between different
MRSA and MSSA strains (p,0.05) and can effectively kill bacteria
at 45 mg/mL. While both human and bovine CAT have more
than 100 mg/mL MIC values. In order to detail CTL antimicro-
bial activity, we further determined the killing rate of CTL. Time-
killing kinetic assays were performed against S. aureus (ATCC
25923). As shown in Figure 1, CTL acts very rapidly against S.
aureus. AT concentration 26MIC CTL present 4 logs bacterial
killing at within 20 min of treatment and 100% within 40 min
(Figure 1A). Moreover, at MIC, CTL reaches 100% bacterial
killing within 60 min of treatment. This killing assay was continued
till 24 h (Figure 1B) and bacteria were unable to grow further
during 24 h. As CTL is the most active, we hypothesized this
fragment is more resistant to proteases produced by S. aureus. In
order to demonstrate the stability of CTL compared to human and
bovine CAT, we incubated the three peptides with the superna-
tants of four different S. aureus strains.
Analysis of the proteolytic cleavage of catestatin (h/
bCAT) and cateslytin (CTL) in the presence of S. aureus
strain supernatants
S. aureus agr and sar regulate expression of proteases, which often
are modulated by SarA regulator during biofilm formation. [33]
These proteases are mostly expressed in the late growth phase and
secreted in the extracellular environment to facilitate the bacterial
spread. [34] As described above, S. aureus supernatants were
prepared by the extended incubation period and are rich in
proteases. Four S. aureus strains were tested for these experiments:
two of them are referenced strains (ATCC 49775 and ATCC
25923), while two strains (S1 and S2) were isolated from the
patients of Strasbourg hospital. S1 is a MRSA (methicillin resistant
S. aureus) and S2 is a MSSA (methicillin sensitive S. aureus). The
synthetic peptides were incubated with S. aureus supernatants and
were separated by RP-HPLC (Figure 2 A, C, E). The HPLC
profiles of CAT and CTL are compared with HPLC profiles of
MHB medium and S. aureus supernatants. Peaks resulting from the
bacterial degradation were analyzed by automatic Edman
sequencing and MALDI-TOF. In contrast to bovine and human
CAT (Figure 2A, 2C), CTL is not degraded (Figure 2E).
HPLC of bCAT (Figure 2A) indicates 2 major peaks, eluted at
38.7 and 40 min, corresponding to full-length peptide according to
sequencing and MALDI-TOF mass spectrometry (2426 Da)
(Figure 3). Presence of these 2 isoforms may be related to beta-
turn conformation induced by proline residue in position 360 and
its isomeric state (cis/trans). [35] In MHB medium, bCAT was not
processed. Whereas, in presence of culture supernatants (S49775,
S25923 and S1), bCAT was processed to generate fragments
eluted at 38.3 and 38.6 min (Figure 2A). Sequencing and MALDI-
TOF analysis indicate that these 2 fragments correspond to the
isoforms of bCgA349–364 (1782 Da) (Figure 3). In presence of
culture supernatant of S2, bCAT was largely cleaved to generate
fragments eluted at 28.0, 36.6 and 37.5 min (Figure 2A).
Sequencing and MALDI-TOF analysis indicate that these
fragments correspond to bCgA350–356 (826 Da) and the 2 isoforms
of bCgA357–364 (887 Da) (Figure 3).
Moreover, the HPLC profile of hCAT (Figure 2C) showed one
major peak at 38 min that corresponds to the full-length peptide
according to sequencing and MALDI-TOF mass spectrometry
(2327 Da) (Figure 3). In presence of MHB medium, hCAT was not
cleaved. However, after incubation with S49775, S25923 and S1,
hCAT was partially processed to generate a fragment eluted at
36 min. Sequencing and MALDI-TOF analysis indicated that this
fragment corresponds to hCgA357–372 (1780 Da) (Figure 3). In
presence of supernatant S2, hCAT was completely cleaved to
generate fragments eluted at 28.5 and 33 min (Figure 2C).
Sequencing and MALDI-TOF analysis indicated that these
fragments correspond to hCgA358–364 (840 Da) and hCgA365–372
(871 Da) (Figure 3).
Finally, the shortest peptide bCTL (bCTL, CgA344–358), is
eluted as a single peak (Figure 2E) and is not degraded by any of
the staphylococcal strains tested.
Interestingly, incubation of synthetic peptides with bacterial
supernatants supplemented with protease inhibitors, prevents the
peptide degradation (Figure 2B, D, F). HPLC profiles of bCAT
(Figure 2B: chromatogram 2–5) indicate that it is not cleaved by any
of the four strain supernatants tested in presence of protease
inhibitors. Similar results were obtained for hCAT (Figure 2D:
chromatogram 2–5). In addition, CTL remains unaffected by S.
aureus supernatants with or without protease inhibitors (Figure 2E,
F).
The proteolytic cleavage sites of bCAT and hCAT obtained
after incubation with S49775, S25923 and S1 were identical
(Figure 3). They corresponded to the peptide bonds L3482S349
and L356–S357 for bCAT and hCAT, respectively. With S2, they
correspond to the peptide bonds S3492F350+G3562F357 and
S3572F358+G3642F365 for bCAT and hCAT, respectively. It is
important to point out that the short peptide bCTL (bCgA344–358)
derived from CAT was not cleaved by S. aureus proteases
(Figure 2E, F) demonstrating that CTL resists to the proteolytic
cocktail produced by S. aureus.
Discussion
Due to continuous resistance development by S. aureus, the interest
for natural AMPs is increasing because some of them display potent
antibacterial activity. However, secondary reactions such as
hemolytic activity, [36] limit their use as systemic anti-infective
drugs. Until recently, no such reaction was reported for the
antimicrobial Cgs-derived peptides in the literature. Several CgA-
derived peptides were previously characterized to display antimi-
crobial properties, [9] however, data concerning killing of S. aureus is
not reported. CAT was previously reported, to be active against
different bacterial strains at micromolar range. [24] CTL is well
characterized for antimicrobial activity against Micrococcus luteus, few
yeasts and fungal strains. Moreover, it is not hemolytic for human
erythrocytes. [5]. In the present study, for the first time, we brought
to light the antibacterial activity of CTL against different strains of S.
aureus with a MIC value of 37–45 mg/mL (Table 1).
In vivo, a cross talk is established via dynamics of the interactions
between host and bacteria. Many bacterial strains express a variety
of proteases, ranging from non-specific and powerful enzymes that
degrade many proteins involved in innate immunity, to proteases
that are extremely specific in their mode of action. [37] Here, we
questioned whether S. aureus proteases can cleave the three CgA-
derived peptides studied. This proteolytic degradation could
explain the 3–4 fold difference observed in antibacterial activity.
To address this issue, we hypothesized that the human and bovine
CAT peptides are degraded by the staphylococcal proteases and
that CTL resists to the degradation and maintains its activity.
Therefore, we tested the effect of four staphylococcal supernatants
and demonstrated that bovine and human CAT are similarly
Cateslytin and S. aureus
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degraded to generate inactive fragments, while CTL is not
degraded. For bovine and human CAT, the cleavage sites induced
by the supernatants are different. For S2 these correspond to the
cleavage of S-F/G-F. Whereas, for ATCC49775, ATCC25923,
and S1, it corresponds to cleavage of L-S (Figure 3). Upon
cleavage by S. aureus proteases, the CAT peptides are no longer
active against S. aureus. Previous data showed that bovine CgA344–
351 and CgA348–358 display an antimicrobial activity against
Micrococcus luteus at 20 mM, suggesting that L348/356 is important
for its antibacterial activity. [5] Furthermore, in the protease
inhibition assay, we demonstrated that degradation of human and
bovine CAT can be prevented by the use of protease inhibitors.
CTL maintains its position either with or without protease
inhibitors indicating that proteases have no effect on the CTL.
Figure 2. HPLC chromatograms of bCAT, hCAT and CTL alone or with different bacterial strain supernatants, with or without
protease inhibitors. (A): Alignment of the HPLC chromatograms corresponding to: (1) bCAT, (2) bCAT+MHB, (3) bCAT+S49775, (4) bCAT+S25923 (5)
bCAT+S1 (6) bCAT+S2. (B): Alignment of the HPLC chromatograms corresponding to: (1) bCAT, (2) bCAT+Pi+S49775, (3) bCAT+Pi+S25923 (4)
bCAT+Pi+S1 (5) bCAT+Pi+S2. (C): Alignment of the HPLC chromatograms corresponding to: (1) hCAT, (2) hCAT+MHB, (3) hCAT+S49775, (4)
hCAT+S25923 (5) hCAT+S1 (6) hCAT+S2. (D): Alignment of the HPLC chromatograms corresponding to: (1) hCAT, (2) hCAT+Pi+S49775, (3)
hCAT+Pi+S25923 (4) hCAT+Pi+S1 (5) hCAT+Pi+S2. (E): Alignment of the HPLC chromatograms corresponding to: (1) bCTL, (2) bCTL+MHB, (3)
bCTL+S49775, (4) bCTL+S25923 (5) bCTL+S1 (6) bCTL+S2. (F): Alignment of the HPLC chromatograms corresponding to: (1) bCTL, (2) bCTL+Pi+S49775,
(3) bCTL+Pi+S25923 (4) bCTL+Pi+S1 (5) bCTL+Pi+S2.
doi:10.1371/journal.pone.0068993.g002
Cateslytin and S. aureus
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The biosynthesis of CTL results by the action of prohormone
convertases PC1/2 present in the granular matrix of chromaffin
cells. [2,38] The prohormone thiol protease (PTP) was also
reported to be essential for CAT synthesis (bCgA344–364) by
cleaving D-R and L-R. [38] In addition, in chromaffin secretory
vesicles, the cysteine protease cathepsin L (CTSL) [39] generates
CTL by the additional cleavage R-G of CAT. CAT fragment is
known to activate the neutrophils by inducing extra-cellular
calcium influx in human neutrophils via calmodulin-regulated
calcium independent phospholipase A2. [11] Here, we demon-
strate that CTL is resistant to the degradation by staphylococcal
proteases, which strengthens the involvement of this CgA-derived
domain in innate immunity. [10,40].
The primary structures of CAT and CTL are highly conserved
during evolution (Figure 4). Arginine ratio of these peptide
sequences is important, since it modulates the interaction with
negatively charges of the microorganism’s membranes. In
addition, it was previously shown that arginine residues have a
high tendency to interact with the lipids as suggested for other
peptides, such as HIV-1 transcriptional activator Tat protein.
[41,42] For hCAT, bCAT, and bCTL the arginine ratios are 15%,
23%, and 33% respectively. High arginine ratio of bCTL supports
a strong interaction with the negatively charged lipid bilayer as
compared to the both CAT. Structure activity relationship of CTL
with bacterial membrane is also demonstrated by recent exper-
iments concerning the CTL derived peptide with a hydrophobic
N-terminal end FLE-CTL (FLE-RSMRLSFRARGYGFR) (5R).
With the help of HPLC and antimicrobial assays, we have shown
that this synthetic peptide is inactive against S. aureus at 400 mg/
mL and interacts strongly with bacterial membrane. In contrast,
the shorter peptide that is lacking the C-terminal end (YGFR) of
CTL: FLE-RSMRLSFRARG, displays antibacterial activities at
200 mg/mL (data not shown). Thus, CTL sequence possesses the
cationic amphipathic features to exhibit potent antimicrobial
activities.
Concerning its secondary structure, an aggregated antiparallel
beta sheet structure was previously reported for CTL [43] by CD
(Circular Dichroism) and ATR (Attenuated total reflectance)
experiments, whereas hCAT and bCAT form short helical
structures (residue 7 to residue 11) in the presence of high
concentrations of DPC, as confirmed by CD and NMR (Nuclear
magnetic resonance) experiments. [44] CTL adopts a major b-
sheet character only on negatively charged membranes, whereas it
is essentially unstructured in water. These b-sheet formations give
a much more stability to peptide than the helical formation
reported for CAT. [44] In addition, the (HR-MAS) 1H NMR
analysis of CTL indicates that the arginine and hydrophobic
residues are in close proximity, thus creating a deep penetration of
charged residues into the membrane. [42] Therefore, the
electrostatic interaction between positively charged arginine
residues and negatively charged lipids appears to be responsible
for binding of CTL to the lipid bilayer and the aromatic residues
stabilize the lipid-peptide interaction.
In our group, we recently evaluated the synergistic effect of
three CgA-derived peptides (CAT, CTL and amidated CTL) with
antibiotics and demonstrated that this co-treatment induce a
reduction of the antibiotics concentration used and can potentiate
their activities. Antimicrobial assays were carried out by combin-
ing the AMPs at concentration below the MIC. The comparison
was made with antibiotic or peptide separately at the same doses.
For all these experiments, we evaluated the Fractional Inhibitory
Concentration (FIC) of CgA-derived peptides combined with
Minocyclin or Voriconazole. FIC corresponds to a synergistic
effect in the range of #0.5, an additive effect when it is between
.0.5 and ,2, and an antagonistic effect when it is .2. [45] For
the combination of amidated CTL and Minocyclin, we obtained a
FIC of 0.37 against S. aureus, and for CTL and Voriconazole, we
obtained a FIC of 0.25, and 0.5 against Candida albicans and
Candida tropicalis respectively. [10] Regarding these data, one could
imagine a mechanism in which, the peptides could favor
destabilization of bacterial membrane, thus allowing the antibiot-
ics to rapidly penetrate inside bacterial cells to reaching their site of
action. These in vitro results are likely to occur in vivo, especially
during systemic inflammation. Indeed, sepsis triggers numerous
Figure 3. The proteolytic cleavage sites induced after treatment of bCAT, hCAT and CTL with different S. aureus strains
(ATCC25923, ATCC49775, S1 and S2). The experimental molecular masses obtained after MALDI-TOF analysis, are indicated.
doi:10.1371/journal.pone.0068993.g003
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changes in proteases and inhibitors activity. [46] These regulations
have been strongly related with sepsis severity. [47] Under such
influences, CAT and CTL could even be difficult to release, owing
to structural modifications of CgA, [48] due to sepsis-related
oxidative stress. These modifications include oxidation of methi-
onine, aromatic residues, glycanes, phosphorylation and also
aggregation of the complete protein that might prevent the
processing of CgA to produce active antimicrobial peptides. The
structure-function relationship of AMPs is also very important to
unravel the regular pattern of antibacterial activity. It has been
previously demonstrated, that selective end tagging or short
hydrophobic stretches can be, added to increase AMPs activity.
[49,50] Recently, we studied the properties of a modified CTL by
inserting cysteine at C-terminal. This modified CTL was used to
develop antimicrobial polymer coatings via alternative deposition
of polyelectrolytes conjugated to CTL-C. [51] Activity of CTL is
not altered, even with this modification or when inserted into PEM
(Polyelectrolyte multilayer) coatings. Moreover, it is non-toxic for
human gingival fibroblast. [51].
To conclude, for the first time we present the involvement of
staphylococcal proteases on the cleavage of antimicrobial CgA-
derived peptides. As the CTL domain is resistant to staphylococcal
proteases, it constitutes a promising natural antibacterial peptide
for further studies.
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